Evidence map›Paper›PMID 22654848›Full record

ArticleFrontiers in endocrinology2011

Mouse models of follicular and papillary thyroid cancer progression.

Marika A Russo, Valeria G Antico Arciuch, Antonio Di Cristofano

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Mouse models of thyroid cancer: A 2015 update.Molecular and cellular endocrinology · 2016
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marika A RussoDepartment of Developmental and Molecular Biology, Albert Einstein College of Medicine Bronx, NY, USA.
Valeria G Antico Arciuch
Antonio Di Cristofano

Funding

Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancerR01CA128943 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI DI CRISTOFANO, ANTONIO · 2009 to 2024
$5.8M
NCI NIH HHS R01 CA128943
6 · The paper itself

Abstract

A significant number of well-differentiated thyroid cancers progress or recur, becoming resistant to current therapeutic options. Mouse models recapitulating the genetic and histological features of advanced thyroid cancer have been an invaluable tool to dissect the mechanisms involved in the progression from indolent, well differentiated tumors to aggressive, poorly differentiated carcinomas, and to identify novel therapeutic targets. In this review, we focus on the lessons learned from models of epithelial cell-derived thyroid cancer showing progression from hyperplastic lesions to locally invasive and metastatic carcinomas.

Indexed as

cancermouseprogressionthyroid

Identifiers

PMID22654848
PMCPMC3356054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.